Joanne L. Blum

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine · 2018 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Javier Cortés, Joyce O’Shaughnessy, David Loesch et al. · The Lancet · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +9

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

Nancy U. Lin, Véronique Dièras, Devchand Paul et al. · Clinical Cancer Research · 2009 · 663 citations · Full text

Medicine, Oncology, Breast Oncology +15

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2009 · 586 citations

Medicine, Oncology, Pharmacology +11

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2006 · 540 citations · Full text

Medicine, Oncology, Pharmacology +17